Online Pharmacy, Tramadol, Paxil, antibiotics, amoxicillin, zithromax, Rx Online, pharmaceuticals, DHEA, prescription medications, prescription drugs.

Drugs online research references

Clin Transplant. 1996 Dec;10(6 Pt 1):550-5.
Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.

Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.

Unit of Nephrology, Ospedali Riuniti di Bergamo, Italy.

Cytomegalovirus (CMV) infection is still a problem for organ transplant recipients despite studies that long-term prophylaxis with high dose of acyclovir or ganciclovir given to all organ recipients may limit the consequences of infection and disease. In the present report of 160 consecutive renal transplant patients, we used a diagnostic assay for CMV antigenemia (detection of CMV antigen in peripheral blood leukocytes) and treated with ganciclovir only those patients who had a positive test. No patient in this series had routine prophylaxis. Out of 160 patients, 71 had clinical and/or laboratory signs of infection, and were tested for early antigen in peripheral leukocytes. The test was positive in 35, all of whom received a course of 3 wk ganciclovir treatment which effectively cured CMV in 34 count of 35. One patient was ganciclovir-resistant, but responded to foscarnet. None of the 36 patients who had no early antigenemia and did not receive treatment developed the disease. The treatment was extremely well tolerated in all our patients with no adverse events. Thus, even though this was not a controlled study, our present results may be taken to indicate that long-term acyclovir or ganciclovir for all organ transplant recipients might be no longer totally justified. We conclude that detecting viral antigen in circulating leukocytes identifies patients who are indeed at risk of developing severe CMV disease. When these patients are treated early enough, CMV is eliminated with a relatively short course of ganciclovir, which has virtually no side effects.

online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8996777&dopt=Abstract

Oftalmologia. 1998;42(2):37-41.
[Acyclovir treatment--its effect on visual acuity and the rate of recurrences in herpetic keratitis]

[Article in Romanian]

Corina P.

Clinica Oftalmologica Venizelios-Iraklio, Grecia.

We treated a number of 141 patients suffering of herpetic keratitis--34 were treated with Acyclovir in the first 72 hours the symptoms started, 42 were treated with Acyclovir after this interval and 65 were treated with IDU. We compared visual acuity after six month and we proved that those that were treated with Acyclovir had the same or better visual performances in most cases. Recurrence rate was 0% in the first year and 2.94% in the second year for those witch were treated with Acyclovir in the first 72 hours symptoms started and 2.94% in the first year and 14.71% in the second year for those treated with Acyclovir after this interval. Patients treated with IDU had suffered 23.53% recurrences in the first year and 41.18% recurrences in the second year. Acyclovir treatment and its precociousness protect patients sight and reduce number of recurrences.

online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9932353&dopt=Abstract

Zhonghua Gan Zang Bing Za Zhi. 2001 Aug;9(4):209-11.
[Experimental study on the effect of combination therapy with lamivudine and famciclovir against duck hepatitis B virus in vivo]

[Article in Chinese]

Chen Y, Guo S, Qi Z, Huang A.

Institute for Viral Hepatitis, Chongqing University of Medical Sciences, Chongqing 400010, China.

OBJECTIVE: To study the antiviral effect of combination therapy with the nucleoside analog lamivudine and famciclovir on duck hepatitis virus (DHBV) in vivo. METHODS: The Chongqing duck hepatitis B model was treated with lamivudine and famciclovir by intragastric administration for 4 weeks. DHBV DNA and DHBsAg in serum were observed by serum dot-blot hybridization and ELISA. ALT and AST in serum were also detected. Histological observation on the duck liver was done simultaneously. The trial was contrasted with a single acyclovir (ACV), famciclovir (FCV), or Lamivudine (3TC). RESULTS: Combination therapy with Lamivudine and famciclovir could significantly reduce the serum DHBV DNA level. After stopping the treatment for 1 week, serum DHBV DNA level did not return significantly. The change of DHBsAg was similar to DHBV DNA. The level of ALT, AST, and the features of liver histopathology in combination-treated ducks were not different from those in control ducks. CONCLUSIONS: The study confirms that combination therapy is superior to single antiviral agent in vivo for ducks with chronic DHBV carrier.

online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11602049&dopt=Abstract

online pharmacies || Hair Million herbal formula for hair loss and hair growth || Tramadol || Antibiotics and prescription medications online literature || Antibiotics